28.3 C
Vientiane
Wednesday, July 9, 2025
spot_img
Home Blog Page 101

Moonkie Unveils Hug & Go Toddler Backpack Ahead of International Children’s Day

A Cozy Companion for Young Explorers, Designed for the Needs of Today’s Families


CALIFORNIA, US – Media OutReach Newswire – 30 May 2025 – Ahead of International Children’s Day, Moonkie—the modern baby and toddler brand—proudly introduces the Moonkie Hug & Go™ Toddler Backpack, a thoughtfully designed essential that meets the evolving needs of modern parenting. Known for its minimalist design and everyday functionality, Moonkie continues its mission of nurturing early childhood development with products that blend emotional connection and practical utility.

The Moonkie Hug & Go™ toddler backpack is designed for families seeking age-appropriate gear that empowers toddlers while maintaining emotional reassurance. Featuring a child-sized backpack with a removable plush companion, it encourages independence through everyday routines—while offering comfort during transitions and new experiences.

A Backpack Designed for Growth—and Hugs

Inspired by Montessori principles, the Hug & Go is more than a backpack; it’s a developmental tool. Sized perfectly for small shoulders, it encourages toddlers to carry their own essentials while the attached plush companion provides emotional reassurance during transitions like daycare drop-offs, travel, or new adventures.

Why it matters

  • Emotional resilience: The soft plush buddy helps soothe separation anxiety, turning moments of uncertainty into opportunities for growth.
  • Safety-first design: Padded straps, embroidered details (no choking hazards), and lightweight materials prioritize comfort and security.
  • Confidence-building: Gives toddlers a sense of ownership (“I can do it myself!”) while easing parental worries.

From Insight to Intention

Moonkie’s design team recognized a universal parenting challenge: toddlers crave independence but still need comfort. “The Hug & Go bridges that gap,” says Cindy M., Product Manager at Moonkie. “It’s a backpack that carries both snacks and emotional support—helping kids feel brave as they explore their world.”

Built for Real Life

  • Parent-approved: Lightweight, compact design (even fits under airplane seats!), durable fabric, and easy-to-clean surfaces
  • Gift-ready: Three charming characters—Rosie Hop the Bunny, Babu the Elephant, and Mossy the Reindeer
  • Accessible luxury: Priced at $32.99 / €28.99 / SR 124.00, the Hug & Go is a charming yet practical gift for birthdays, holidays, or “just because”

Celebrate International Children’s Day with a gift that supports growth, sparks joy, and helps toddlers take their first steps into the world with confidence.

For more information, visit moonkieshop.com
Follow Moonkie on:
Instagram: @moonkie_official
TikTok: @moonkie_official
Facebook: Moonkie Official
YouTube: Moonkie

Hashtag: #Moonkie

The issuer is solely responsible for the content of this announcement.

NEW THERAPY FOR CHILDREN WITH GROWTH HORMONE DEFICIENCY APPROVED IN AUSTRALIA

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric growth hormone deficiency.[1]

SINGAPORE, May 30, 2025 /PRNewswire/ — Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the Australian registration of SKYTROFA® (lonapegsomatropin) as a new once-weekly injectable therapy for paediatric growth hormone deficiency (GHD).[2] The Therapeutic Goods Administration (TGA) has approved SKYTROFA as a treatment for “growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion”.[1,2]

GHD is a rare disease affecting around 2-3/10,000 Australians, with approximately 2,000 children thought to be living with the condition.[3] It occurs when the pituitary gland, located at the base of the brain, does not produce an adequate level of growth hormone, which is essential for promoting healthy growth in children.[3] In children, GHD is typically characterised by slow height growth, resulting in short stature, and may also include delayed puberty, impaired hair growth and headaches.[3] The goal of treatment for GHD is to restore normal levels of growth hormone in the body, reduce physical symptoms, enhance metabolic health and improve quality of life.[3]

ST Chief Executive Officer, Mr Carlo Montagner, said the TGA approval of SKYTROFA demonstrated the company’s ongoing mission to support patients with rare diseases in Australia and the Asia-Pacific region.

“We are delighted to have secured TGA registration of SKYTROFA for eligible Australian children with growth hormone deficiency. Beyond short stature, children and adolescents with the condition may experience considerable physical and psychosocial impacts on their daily life, such as poor concentration, decreased strength or muscle development, fatigue, and reduced quality of life.[4]

“This announcement also represents a significant milestone for Specialised Therapeutics, marking the second endocrinology therapy we have successfully registered in Australia, following the approval of YORVIPATH® (palopegteriparatide) earlier this year,” said Mr Montagner.

SKYTROFA is being registered in Australia by ST, under an exclusive distribution agreement with biopharmaceutical company Ascendis Pharma A/S that covers Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam. The Australian registration of SKYTROFA follows approvals issued to Ascendis Pharma by the United States Food and Drug Administration (US FDA)[5] in August 2021 and the European Medicines Agency (EMA)[6] in January 2022.

Developed using Ascendis Pharma’s proprietary TransConTM platform, SKYTROFA is delivered as a subcutaneous injection, available in various strengths.[2] The starting dose depends on the patient’s body weight and is then adjusted individually by the treating endocrinologist based on the patient’s response to treatment.[2]

Ascendis Pharma’s innovative TransConTM technology platform is designed to create new therapies with the potential to optimise therapeutic effect, including improving treatment efficacy, safety and dosing frequency.[7] TransConTM molecules have three components: an unmodified parent drug, an inert TransCon™ carrier that protects it, and a TransConTM linker that temporarily binds the two.[7]

SKYTROFA is a prodrug of somatropin administered once weekly, designed to provide sustained release of active, unmodified somatropin.[6] This allows the medicine to slowly release unmodified growth hormone into the body over the course of one week, removing the need for daily injections.

SKYTROFA consists of three components: the parent drug somatropin, an inert methyloxypolyethlene glycol carrier (mPEG), and a proprietary TransConTM linker that transiently binds the other two elements.[8,9] While bound, the carrier inactivates the somatropin and shields it from renal excretion and receptor-mediated clearance.[10] Following injection, autocleavage of the linker occurs under physiologic conditions, and SKYTROFA releases fully active, unmodified somatropin in a predictable manner.[10]

The TGA registration of SKYTROFA was based on the results of Ascendis Pharma’s three pivotal Phase 3 clinical trials, heiGHt, fliGHt and enliGHten, which collectively treated more than 300 paediatric patients diagnosed with GHD, including from Australia.[2,8,11,12]

SKYTROFA was generally well-tolerated across all three clinical trials. The most commonly reported adverse events include viral infections, fever, cough, nausea and vomiting, haemorrhage, diarrhoea, abdominal pain, arthralgia, arthritis, and increased blood phosphate levels.

PBS Information: SKYTROFA is not listed on the Pharmaceutical Benefits Scheme (PBS).

About Specialised Therapeutics

Founded in 2007, Specialised Therapeutics is the region’s largest independent specialty pharmaceutical company, providing new therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions. The ST mission is to provide specialty therapies where there is an unmet need. The company’s broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. ST is a member of the World Orphan Drug Alliance (WODA).

Additional information can be found at www.stbiopharma.com

About Ascendis Pharma

Ascendis Pharma is a global biopharmaceutical company focused on applying its innovative TransConTM technology platform to make a meaningful difference for patients. Guided by core values of Patients, Science, and Passion, and following its algorithm for product innovation, Ascendis Pharma applies TransConTM to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit: ascendispharma.com to learn more.

About Paediatric Growth Hormone Deficiency

Paediatric growth hormone deficiency (GHD) is a serious orphan disease caused when the pituitary gland does not produce enough growth hormone. Physiological levels of growth hormone are required for overall endocrine health and development of healthy bone, muscle, and adipose tissue. Children with GHD are characterised by short stature and may also experience metabolic abnormalities, psychosocial challenges, and an overall poor quality of life. For decades, the standard of care for GHD has been a daily subcutaneous injection of human growth hormone (hGH) to improve growth and overall endocrine health.

About SKYTROFA (lonapegsomatropin)

Once-weekly SKYTROFA is a prodrug of somatropin, designed to provide sustained release of unmodified somatropin. The unmodified, unbound somatropin released from lonapegsomatropin has the same 191 amino acid sequence and size as endogenous growth hormone.[8]

SKYTROFA single-use, prefilled cartridges are manufactured in nine dosage strengths, allowing for convenient dosing flexibility. They are designed for use only with the SKYTROFA Auto-Injector and may be stored at room temperature for up to six months. The recommended dose of SKYTROFA for treatment-naïve children with growth hormone deficiency and those switching from daily somatropin is 0.24 mg/kg body weight, administered once weekly.[2] The dose may be adjusted based on the child’s weight and insulin-like growth factor-1 standard deviation score (IGF-1 SDS).[2]

SKYTROFA was studied in over 300 children with GHD across the Phase 3 program, which consisted of the HeiGHt Trial[8] (for treatment-naïve patients), the FliGHt Trial[11] (for treatment-experienced patients), and the EnliGHten Trial[12] (a long-term extension trial). Patients who completed the HeiGHt or FliGHt Trials were able to continue in EnliGHten, with some on lonapegsomatropin treatment for over four years. Ascendis Pharma is also conducting the ongoing open-label portion of the global Phase 3 ForesiGHt Trial of SKYTROFA in adults with GHD.

Ascendis®, TransConTM and SKYTROFA®  are trademarks owned by the Ascendis Pharma group (NASDAQ: ASND).

About TransConTM Technologies

TransCon refers to “transient conjugation”. Ascendis Pharma’s innovative technology platform to create new therapies designed to potentially optimise therapeutic effect, including improving efficacy, safety and dosing frequency. TransCon molecules have three components: an unmodified parent drug, an inert TransCon carrier that protects it, and a TransCon linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic conditions (e.g. pH and temperature) initiate the release of the active, unmodified parent drug in a predictable manner. Because the parent drug is unmodified, its original mode of action is expected to be maintained. TransCon technology can be applied to a broad variety of therapeutics, such as antibodies, antibody fragments, proteins, peptides, or small molecules, and can be designed for systemic or local administration.

References:

[1] Therapeutic Goods Administration. Australian Register of Therapeutic Goods (ARTG). Available at: https://www.tga.gov.au/resources/artg?keywords=skytrofa. [Accessed May 2025].
[2] SKYTROFA (lonapegsomatropin) Product Information, Australia.
[3] Australian Pituitary Foundation. Factsheet: A Guide To Growth Hormone Deficiency, 2023. Available at: https://pituitary.asn.au/wp-content/uploads/2023/09/APF-Growth-Hormone-Deficiency-Fact-Sheet-2023_Digital-Final.pdf [Accessed May 2025].
[4] Brod M et al. Qual Life Res. 2017 Jul;26(7):1673-1686.
[5] US Food and Drug Administration (FDA). Drug Approval Package: SKYTROFA. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761177Orig1s000TOC.cfm [Accessed May 2025].
[6] European Medicines Agency (EMA). Skytrofa (previously Lonapegsomatropin Ascendis Pharma), January 2022. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa [Accessed May 2025].
[7] Ascendis Pharma A/S. TransCon: A powerful technology platform central to our innovative approach. Available at: https://ascendispharma.com/technology/ [Accessed May 2025].
[8] Thornton PS, et al. J Clin Endocrinol Metab. 2021 Oct;106(11):3184-3195.
[9] SKYTROFA® [package insert]. Palo Alto, CA: Ascendis Pharma, Inc.
[10] Sprogøe K, et al. Endocr Connect. 2017;6(8):R171-r181.
[11] Maniatis AK, et al. Horm Res Paediatr. 2022 Mar;95(3):233-243.
[12] Maniatis AK, et al. J Clin Endocrinol Metab. 2022 Jun;107(7):e2680-e2689.

 

HeyGears Launches UltraCraft Reflex RS Turbo with Enhanced Screen Technology

The UltraCraft Reflex RS Turbo provides a turbo-charged upgrade to the best-selling Reflex RS, delivering a longer lifespan screen and high precision whilst maintaining a fast printing speed. Exclusive launch offers are now available at HeyGears’ online store.

IRVINE, Calif., May 30, 2025 /PRNewswire/ — HeyGears, a leading innovator in 3D printing solutions, has launched the UltraCraft Reflex RS Turbo, an enhanced version of its popular Reflex RS 3D printer. The launch marks a significant step as the company celebrates its 10th anniversary, reflecting a decade of continuous improvements to meet the practical needs of 3D printing professionals.


UltraCraft Reflex RS Turbo

Designed for creators and professionals who value detail and reliability, the RS Turbo introduces a main screen enhancement that improves both detail sharpness and surface quality, while maintaining the trusted performance of HeyGears’ UltraCraft Reflex series of 3D printers.

The Outstanding Enhancements with UltraCraft Reflex RS Turbo

The RS Turbo introduces several key upgrades:

Enhanced Amber Screen – A 566:1 contrast ratio enables sharper print details and minimizes light leakage for better details and surface results.

C5 Grade Z-axis Module – Provides precision motion control with movement errors controlled within ±2 μm for improved dimensional accuracy.

Dynamic Motion Algorithm 3.0 – Allows for increased print speeds by up to 33%*, optimizing workflow without compromising quality.

*Data sourced from HeyGears Lab, utilizing PAWW10 water-washable resin, compared to conventional motion control 3D printing. The exact speed increase may vary based on model.

The RS Turbo also features an upgraded polarizer layer with excellent UV resistance and thermal stability. This enhances screen longevity, supporting over 1 million* printed layers with consistent UV exposure across the entire build surface.

*Estimates based on PAWW20 water-washable resin – results of other resins may vary.

Anniversary & Launch Deals Now Available

RS Turbo Launch Activity
RS Turbo Launch Activity

In celebration of its 10th anniversary, HeyGears is offering limited-time launch promotions for RS Turbo buyers as well as other purchases:

Instant 20% OFF – Automatic discount on all RS Turbo purchases.

Two Flash Sale Rounds – First come, first served with special pricing.

Free PAS10 Resin – One complimentary bottle with each RS Turbo purchase.

Exclusive Bundle Deals – Additional value-packed options available during the promotion.

The UltraCraft Reflex RS Turbo is available now through HeyGears’ official store. For detailed specifications, pricing, or to access launch offers, visit store.heygears.com

ValueLabs Announces Strategic Pivot—Exclusively Offering Outcome-Based Engagements Globally

Company shifts away from Time & Materials contracts for all new clients, embracing outcome-driven, AI-powered delivery models.

HYDERABAD, India, May 30, 2025 /PRNewswire/ — ValueLabs, a global leader in Agentic AI Services, today announced a strategic pivot, transitioning fully away from traditional Time & Materials (T&M) contracts for new clients across all major markets. This milestone reinforces ValueLabs’ commitment to outcomes, innovation, and its transformative Enterprise OS platform—AiDE®.

As of today, all new engagements with ValueLabs will leverage outcome-based delivery models, including Managed Services (MSP), fixed-price engagements, productivity-linked pricing, and value-sharing agreements. This strategic shift aligns ValueLabs’ incentives with clients, ensuring measurable business impact, predictable outcomes, and accelerated value realization.

The decision comes on the heels of rapid adoption and widespread success of AiDE®, ValueLabs’ proprietary Agentic AI platform. AiDE acts as an Enterprise Operating System, embedding autonomous AI agents into core enterprise workflows across software engineering, business operations, analytics, and strategic workflows, transforming clients into AI-native enterprises.

Speaking about this strategic pivot, Arjun Rao, Founder and Chairman of ValueLabs, said, “The era of billing hours is behind us. Our clients don’t just want work done—they want measurable outcomes, faster innovation, and business results that matter. With AiDE, we have the confidence, capabilities, and credibility to deliver exactly that. This shift isn’t merely operational; it redefines how technology partners add real value in the Agentic Era.”

Sam Alva, CEO of ValueLabs, reinforced the strategic vision: “We’ve already proven that AiDE-driven delivery significantly accelerates outcomes and improves productivity. We are now aligning our commercial models to reflect this reality. Outcome-based engagements ensure our success is directly tied to our clients’ outcomes. It’s a win-win approach powered by our platform-led, Service-as-Software model—where AiDE transforms everything, everywhere, all at once.”

This announcement positions ValueLabs at the forefront of a fundamental industry shift—from traditional service delivery, towards innovative, outcome-aligned partnerships. Clients from across verticals like Commerce, Healthcare, Insurance, and Travel have already experienced substantial benefits from this model, achieving tangible business impacts including increased speed-to-market, improved operational efficiencies, and measurable financial returns.

About ValueLabs

ValueLabs & AiDE®: Enterprise OS of the Agentic Era
From Engineering to Everything—custom agents powering AI-native enterprises.

Founded in 1997, ValueLabs is a global Agentic AI Services firm helping enterprises reinvent themselves as AI-native organizations. At the core of this transformation is AiDE®—ValueLabs’ proprietary platform and the Enterprise Operating System for the Agentic Era. AiDE integrates custom-built autonomous AI agents seamlessly across software engineering, business operations, analytics, and strategic workflows. With over 7,000 professionals serving more than 300 enterprise clients globally, ValueLabs leverages AiDE and innovative Service-as-Software delivery models to unlock productivity, agility, and sustainable competitive advantage.

 

HeyGears Launches UltraCraft Reflex RS Turbo with Enhanced Screen Technology

IRVINE, Calif., May 30, 2025 /PRNewswire/ — The UltraCraft Reflex RS Turbo provides a turbo-charged upgrade to the best-selling Reflex RS, delivering a longer lifespan screen and high precision whilst maintaining a fast printing speed. Exclusive launch offers are now available at HeyGears’ online store.


UltraCraft Reflex RS Turbo Introduction

HeyGears, a leading innovator in 3D printing solutions, has launched the UltraCraft Reflex RS Turbo, an enhanced version of its popular Reflex RS 3D printer. The launch marks a significant step as the company celebrates its 10th anniversary, reflecting a decade of continuous improvements to meet the practical needs of 3D printing professionals.

Designed for creators and professionals who value detail and reliability, the RS Turbo introduces a main screen enhancement that improves both detail sharpness and surface quality, while maintaining the trusted performance of HeyGears’ UltraCraft Reflex series of 3D printers.

The Outstanding Enhancements with UltraCraft Reflex RS Turbo

The RS Turbo introduces several key upgrades:

Enhanced Amber Screen – A 566:1 contrast ratio enables sharper print details and minimizes light leakage for better details and surface results.

C5 Grade Z-axis Module – Provides precision motion control with movement errors controlled within ±2 μm for improved dimensional accuracy.

Dynamic Motion Algorithm 3.0 – Allows for increased print speeds by up to 33%*, optimizing workflow without compromising quality.

RS Turbo upgrade
RS Turbo upgrade

*Data sourced from HeyGears Lab, utilizing PAWW10 water-washable resin, compared to conventional motion control 3D printing. The exact speed increase may vary based on model.

The RS Turbo also features an upgraded polarizer layer with excellent UV resistance and thermal stability. This enhances screen longevity, supporting over 1 million* printed layers with consistent UV exposure across the entire build surface.

*Estimates based on PAWW20 water-washable resin – results of other resins may vary.

Anniversary & Launch Deals Now Available

In celebration of its 10th anniversary, HeyGears is offering limited-time launch promotions for RS Turbo buyers as well as other purchases:

Instant 20% OFF – Automatic discount on all RS Turbo purchases.

Two Flash Sale Rounds – First come, first served with special pricing.

Free PAS10 Resin – One complimentary bottle with each RS Turbo purchase.

Exclusive Bundle Deals – Additional value-packed options available during the promotion.

The UltraCraft Reflex RS Turbo is available now through HeyGears’ official store. For detailed specifications, pricing, or to access launch offers, visit store.heygears.com 

Kingsoft(3888.HK) Repurchases 1.5 Million Shares for Approximately HKD 51 Million

HONG KONG, May 29, 2025 /PRNewswire/ — On May 29, Kingsoft repurchased 582,000 shares at a cost of about HKD 20 million. The employee stock plan purchased 921,000 shares at a cost of approximately HKD 31 million. The total expenditure amounted to around HKD 51 million.

About Kingsoft Corporation Limited

Kingsoft (3888.HK) is a leading Chinese software and internet service company listed on the Hong Kong Stock Exchange. It has three main subsidiaries: Kingsoft Office, Seasun Holdings and Kingsoft Shiyou. With the implementation of the “transformation toward mobile internet” strategy, Kingsoft has completed a comprehensive transformation in its overall business and management model. The Company has established a strategic layout with office software and interactive entertainment as its pillars, and cloud services and artificial intelligence as its new starting points. Kingsoft has nearly 8,000 employees worldwide and holds a significant market share domestically. For more details, please refer to http://www.kingsoft.com.

 

 

“Made-in-Shanghai” Takes China-chic Brands and Shanghai’s Fashion Ecosystem to Osaka

OSAKA, Japan, May 29, 2025 /PRNewswire/ — More than a fascinating array of creative exhibits, pop-up stores and twin-city forums, “Made-in-Shanghai” is an international showcase of Shanghai’s fashion ecosystem. On May 21st to 25th, the sixth edition of “Made-in-Shanghai” was held in Grand Green Osaka, its first overseas leg, themed under “Lifestyle Trends of Shanghai & Osaka”. More than 1000 exhibits from 90 Shanghai-based brands, covering fashion and accessories, cosmetics, snacks, sportswear, tech-savvy products, handicrafts and more, welcomes consumers and businesses in Osaka with a panorama of Shanghai’s fashion industry.

The exhibits attracted a large number of Japanese consumers.
The exhibits attracted a large number of Japanese consumers.

The high-profile opening ceremony was addressed by Mr. FANG Wei, China’s deputy consul general in Osaka. Hundreds of officials, brand representatives, designers, journalists and KOLs attended the opening ceremony, and tens of thousands of Japanese consumers visited it in the five days.

While the most popular area for consumers was “Shanghai Lab”, a presentation of Shanghai’s fashion and beauty industry blocks was attractive to businesses. Yuyuan Road brought 23 brands from its creative community to Osaka with the narrative of “City-Block Renewal”. It garnered interest from Japanese fashion brands and professionals, who expressed interests in visiting this community. Oriental Beauty Valley presented its 9-brand matrix, demonstrating its beauty industry chain, public services and innovation power. The organizers — Oriental Beauty Valley and Shanghai Comprehensive Industrial Development Zone visited the Japan Office of Shanghai Foreign Investment Promotion Center and famous Japanese enterprises such as Exedy, to deepen cooperation.

At Hankyu Department Store, Chinese designers presented “WINDow of EAST” pop-up stores, attracting officials from Osaka Convention and Tourism Bureau and luxury buyer store owners, along with celebrities, designers, KOLs and consumers.

Adding to the brick-and-mortar stores is the e-commerce solution from Confis. This Japanese company provides local packing, product design, warehousing and channel marketing solutions to the brands participating in this event.

Indeed, “Made-in-Shanghai” champions a two-way service for companies looking to expand overseas and investing in Shanghai, be it creative consultation, assistance in overseas promotion, or cross-border marketing. Curated by Shanghai Design Week, one of the organizers of the event, more than 20 brand managers came to Osaka to explore business opportunities and gain consumer feedback.

“Made-in-Shanghai” is continuing to send shockwaves across the globe, reaching 400 million people. The coverage from The Paper, another organizer of the event, received 3.76 million clicks. 795 media outlets, including AP News, NBC News, Asahi Shimbun and more have covered the event.

Gridora signs inaugural MoU with Abu Dhabi Projects and Infrastructure Centre to accelerate delivery of transport infrastructure projects worth AED 35 billion

ABU DHABI, UAE, May 29, 2025 /PRNewswire/ — Gridora, the new infrastructure platform established by ADQ, IHC and Modon Holding, has signed its first Memorandum of Understanding (MoU) with Abu Dhabi Projects and Infrastructure Centre (ADPIC) for the delivery of high-impact transport infrastructure projects. The agreement marks a key milestone in Gridora’s mission to champion the delivery of strategic infrastructure projects.

H.E. Jassem Mohamed Bu Ataba Al Zaabi, Chairman of Gridora; H.E. Mohamed Ali Al Shorafa,Chairman of the Department of Municipalities and Transport; H.E. Eng. Maysarah Mahmoud Eid, Director General of ADPIC; and Bill O’Regan, Group CEO of Modon Holding, at the Gridora x ADPIC MoU signing.
H.E. Jassem Mohamed Bu Ataba Al Zaabi, Chairman of Gridora; H.E. Mohamed Ali Al Shorafa,Chairman of the Department of Municipalities and Transport; H.E. Eng. Maysarah Mahmoud Eid, Director General of ADPIC; and Bill O’Regan, Group CEO of Modon Holding, at the Gridora x ADPIC MoU signing.

Through this agreement, Gridora and ADPIC will establish a framework for potential collaboration in relation to supporting the development, planning and implementation of strategic infrastructure projects within the Emirate of Abu Dhabi.

The initial focus of the MoU will be to establish a working committee to explore potential opportunities and identify pilot projects, activities and initiatives Gridora could undertake. These would be considered from several projects ADPIC aims to deliver within the emirate, with the centre having been mandated to implement projects with an estimated value of at least AED 35 billion.

His Excellency Jassem Mohamed Bu Ataba Al Zaabi, Chairman of Gridora, said: “Gridora’s expertise and resources will deliver world-class infrastructure, empowering the nation’s ambitious economic and population growth goals. Our MoU with ADPIC reflects our shared commitment to accelerate the implementation of critical transport infrastructure, combining innovation, scale and vision. The delivery of these high-impact infrastructure projects will be transformative to Abu Dhabi, and we look forward to working closely as a trusted infrastructure partner to ADPIC.”

His Excellency Mohamed Ali Al Shorafa, Chairman of the Department of Municipalities and Transport, commented: “This strategic partnership between ADPIC and Gridora underscores a shared focus on creating transport infrastructure that enhances Abu Dhabi’s continued growth as a global city. By leveraging Gridora’s capabilities, this collaboration aims to accelerate project delivery, improve cost efficiency, and deliver long-term value for Abu Dhabi and its communities.”

His Excellency Eng. Maysarah Mahmoud Eid, Director General of ADPIC, said, At ADPIC, we see infrastructure as a powerful enabler of opportunity, economic growth, and long-term sustainability. This MoU with Gridora advances our shared commitment to accelerate the delivery of high-impact projects that enhance connectivity and quality of life across the emirate. By combining our strategic vision with Gridora’s delivery capabilities we are shaping a future-ready emirate that aligns with Abu Dhabi’s strategic vision and long-term goals.”

Bill O’Regan, Group CEO of Modon Holding, said: “With this MoU, we can unlock Gridora’s capability to deliver critical infrastructure, ensuring the long-term growth of the recently announced infrastructure platform. We look forward to seeing Gridora move forward with purpose, enabling world-class cities with cutting edge infrastructure.”

Operating under Modon Holding and established in partnership with ADQ and IHC, Gridora serves as a strategic platform for collaboration with specialist partners and capital providers, enabling the delivery of large-scale, high-impact infrastructure projects. Gridora has adopted a dual-focus business model spanning ‘Infrastructure Projects’ and ‘Infrastructure Investments’, enabling it to lead across the full infrastructure lifecycle.

This MoU with ADPIC marks the first in a series of planned engagements to advance high-impact public-priority infrastructure, enhance and foster long-term collaboration between the public and private sectors and is a testament to the significant scale of Gridora’s business.

About Gridora:

Gridora is a private-sector infrastructure development platform established by ADQ, IHC and Modon Holding to accelerate the delivery of strategic projects across the UAE and beyond. Operating under Modon Holding, Gridora is structured around two core business lines – Infrastructure Projects and Infrastructure Investments – providing end-to-end capabilities from planning through to operations. The platform serves as a catalyst for public-private collaboration, combining the strategic capital, technical expertise and execution scale required to drive long-term impact in the infrastructure sector nationally, regionally and internationally.

About ADPIC

Established in 2023, ADPIC’s vision is to oversee and manage capital projects aimed at enhancing the quality of life for every resident in the Emirate of Abu Dhabi. This involves diverse projects such as housing, infrastructure, tourism, community facilities, and education. ADPIC’s mandate includes managing contracts, reviewing, approving, planning, and designing capital projects. These are overseen by the Centre in close collaboration with relevant entities and stakeholders to ensure quality is maintained while also facilitating efficient project execution in alignment with Abu Dhabi’s strategic goals. Throughout its operations, the Centre is committed to strengthening public-private partnerships and adopting global best practices in sustainability.

For media enquiries contact: press@gridora.com